{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:26:35Z","timestamp":1788143195727,"version":"build-2803163510"},"reference-count":35,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Kirin Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016348","name":"Kyowa Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008572","name":"University of Ottawa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008572","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031148","name":"The Children\u2019s Hospital of Eastern Ontario Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031148","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>X-linked hypophosphatemia (XLH) is a rare disorder characterized by excess fibroblast growth factor 23 (FGF23), leading to chronic hypophosphatemia, osteomalacia, and rickets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate outcomes up to 3 years following initiation of treatment with anti-FGF23 antibody (burosumab) in a real-world setting among individuals with XLH, stratified by age group, including those excluded from clinical trials (&amp;lt;1, 13-17, and \u226565 years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The XLH Disease Monitoring Program is a prospective, longitudinal, long-term-outcomes program for individuals with XLH. This analysis included participants who were burosumab-naive at baseline and who had initiated burosumab between baseline and the Year 1 visit. Changes from baseline in biochemistry, clinical outcomes, and patient-reported outcomes (PROs) were assessed at Year 1 (Y1) and Year 3 (Y3) visits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among participants (n = 139), burosumab led to significant and sustained improvements in mean (SD) serum phosphate z-scores at Y1 and Y3 (change from baseline: 1.4 [1.1]; P &amp;lt; .0001 for each timepoint). Among pediatric participants, serum alkaline phosphatase z-scores, Rickets Severity Scores, and patient-reported pain interference declined significantly at Y1 and Y3; non-significant changes were observed in fatigue and physical function mobility. Adults showed significant improvements in PRO measures of pain, stiffness, and physical function, with higher proportions of participants achieving minimal clinically important differences at Y3 vs Y1. Trends observed in overall cohorts were generally consistent across age sub-groups, with statistical significance reached for many endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This analysis demonstrated the real-world effectiveness of burosumab for XLH, which appears evident across age groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag140","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:45:31Z","timestamp":1775216731000},"page":"2466-2482","source":"Crossref","is-referenced-by-count":2,"title":["Real-world effectiveness of burosumab across age groups: X-linked hypophosphatemia (XLH) Disease Monitoring Program"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-9185","authenticated-orcid":false,"given":"Leanne M","family":"Ward","sequence":"first","affiliation":[{"name":"Children's Hospital of Eastern Ontario, University of Ottawa , Ottawa, ON , K1H 8L1","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1328-6768","authenticated-orcid":false,"given":"Thomas O","family":"Carpenter","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine Departments of Pediatric (Endocrinology), and Orthopedics and Rehabilitation, , New Haven, CT 06510 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamilton","family":"Cassinelli","sequence":"additional","affiliation":[{"name":"Ricardo Guti\u00e9rrez Children's Hospital Department of Endocrinology, , C1425 Buenos Aires ,","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5936-3146","authenticated-orcid":false,"given":"Pablo","family":"Florenzano","sequence":"additional","affiliation":[{"name":"School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile , 8331150 Santiago ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A","family":"Imel","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine Departments of Medicine and Pediatrics, , Indianapolis, IN 46202-3082 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya A","family":"Khan","sequence":"additional","affiliation":[{"name":"McMaster University Division of Endocrinology and Metabolism, , Hamilton, ON , L8S 4L8","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3938-0920","authenticated-orcid":false,"given":"Ben","family":"Johnson","sequence":"additional","affiliation":[{"name":"Kyowa Kirin International plc , Marlow, Buckinghamshire, SL7 1HZ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erru","family":"Yang","sequence":"additional","affiliation":[{"name":"Ultragenyx Pharmaceutical Inc. , Brisbane, CA 94005 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Vincent","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Inc. , Princeton, NJ 08540 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3088-2883","authenticated-orcid":false,"given":"Heather M","family":"Heerssen","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Inc. , Princeton, NJ 08540 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0779-9720","authenticated-orcid":false,"given":"Zhiyi","family":"Li","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Inc. , Princeton, NJ 08540 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill H","family":"Simmons","sequence":"additional","affiliation":[{"name":"School of Medicine, Vanderbilt University , Nashville, TN 37232 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"issue":"7","key":"2026081219562847600_dgag140-B1","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician's guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2026081219562847600_dgag140-B2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s11914-023-00814-6","article-title":"Genetics of diffuse idiopathic skeletal hyperostosis and ossification of the spinal ligaments","volume":"21","author":"Kato","year":"2023","journal-title":"Curr Osteoporos Rep"},{"key":"2026081219562847600_dgag140-B3","doi-asserted-by":"crossref","first-page":"104958","DOI":"10.1016\/j.ejmg.2024.104958","article-title":"Safety and efficacy of burosumab in improving phosphate metabolism, bone health, and quality of life in adolescents with X-linked hypophosphatemic rickets","volume":"70","author":"Baroncelli","year":"2024","journal-title":"Eur J Med Genet"},{"issue":"3","key":"2026081219562847600_dgag140-B4","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026081219562847600_dgag140-B5","doi-asserted-by":"crossref","first-page":"17101","DOI":"10.1038\/nrdp.2017.101","article-title":"Rickets","volume":"3","author":"Carpenter","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2026081219562847600_dgag140-B6","doi-asserted-by":"crossref","first-page":"146","DOI":"10.5395\/rde.2017.42.2.146","article-title":"Dental management of patients with X-linked hypophosphatemia","volume":"42","author":"Lee","year":"2017","journal-title":"Restor Dent Endod"},{"issue":"11","key":"2026081219562847600_dgag140-B7","doi-asserted-by":"crossref","first-page":"e10672","DOI":"10.1002\/jbm4.10672","article-title":"Burosumab and dental abscesses in children with X-linked hypophosphatemia","volume":"6","author":"Gadion","year":"2022","journal-title":"JBMR Plus"},{"issue":"3","key":"2026081219562847600_dgag140-B8","doi-asserted-by":"crossref","first-page":"e1249","DOI":"10.1210\/clinem\/dgab739","article-title":"Musculoskeletal features in adults with X-linked hypophosphatemia: an analysis of clinical trial and survey data","volume":"107","author":"Javaid","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026081219562847600_dgag140-B9","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J Endocr Soc"},{"issue":"8","key":"2026081219562847600_dgag140-B10","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1210\/clinem\/dgaf170","article-title":"X-linked hypophosphatemia management in adults: an international working group clinical practice guideline","volume":"110","author":"Khan","year":"2025","journal-title":"J Clin Endoclinol Metab"},{"key":"2026081219562847600_dgag140-B11","author":"Crysvita\u00ae [Burosumab]"},{"issue":"10189","key":"2026081219562847600_dgag140-B12","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"2026081219562847600_dgag140-B13","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"AXLES 1 investigators. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026081219562847600_dgag140-B14","doi-asserted-by":"crossref","first-page":"e001714","DOI":"10.1136\/rmdopen-2021-001714","article-title":"Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension","volume":"7","author":"Briot","year":"2021","journal-title":"RMD Open"},{"issue":"3","key":"2026081219562847600_dgag140-B15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"2026081219562847600_dgag140-B16","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/10408363.2017.1379945","article-title":"The Canadian laboratory initiative on pediatric reference intervals: a CALIPER white paper","volume":"54","author":"Adeli","year":"2017","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"3","key":"2026081219562847600_dgag140-B17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1053\/j.ajkd.2008.07.036","article-title":"Serum phosphate concentrations in the third national health and nutrition examination survey (NHANES III)","volume":"53","author":"de Boer","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2026081219562847600_dgag140-B18","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1373\/clinchem.2011.177741","article-title":"Closing the gaps in pediatric Laboratory Reference intervals: a CALIPER databaseof 40 biochemical markers in a healthyand multiethnic population of children","volume":"58","author":"Colantonio","year":"2012","journal-title":"Clin Chem"},{"issue":"3","key":"2026081219562847600_dgag140-B19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/tropej\/46.3.132","article-title":"Radiographic scoring method for the assessment of the severity of nutritional rickets","volume":"46","author":"Thacher","year":"2000","journal-title":"J Trop Pediatr"},{"issue":"1","key":"2026081219562847600_dgag140-B20","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s11357-024-01280-3","article-title":"Revisiting the \u201cTimed Up and Go\u201d test: a 12-s cut-off can predict hospitalization-associated functional decline in older adults","volume":"47","author":"Gatenio-Hefling","year":"2025","journal-title":"GeroScience"},{"issue":"24","key":"2026081219562847600_dgag140-B21","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.3390\/jcm12247618","article-title":"Evaluating the minimum clinically important difference and patient acceptable symptom state for the WOMAC osteoarthritis index after unicompartmental knee arthroplasty","volume":"12","author":"Longo","year":"2023","journal-title":"J Clin Med"},{"issue":"11","key":"2026081219562847600_dgag140-B22","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","article-title":"The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested in first wave of adult self-reported health outcome item banks: 2005\u20132008","volume":"63","author":"Cella","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"2026081219562847600_dgag140-B23","author":"Health Measures"},{"issue":"6","key":"2026081219562847600_dgag140-B24","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2214\/ajr.146.6.1253","article-title":"Renal calcium deposition in children: sonographic demonstration of the anderson-carr progression","volume":"146","author":"Patriquin","year":"1986","journal-title":"AJR Am J Roentgenol"},{"key":"2026081219562847600_dgag140-B25"},{"key":"2026081219562847600_dgag140-B26","unstructured":"Supplementary Data Repository. 10.6084\/m9.figshare.31981455"},{"issue":"8","key":"2026081219562847600_dgag140-B27","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/jbmr\/zjaf063","article-title":"Real-world effectiveness of burosumab vs oral phosphate and active vitamin D in adults with X-linked hypophosphatemia","volume":"40","author":"Florenzano","year":"2025","journal-title":"J Bone Min Res"},{"issue":"5","key":"2026081219562847600_dgag140-B28","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s41581-024-00926-x","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphatemia","volume":"21","author":"Haffner","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"2026081219562847600_dgag140-B29","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bone.2019.06.025","article-title":"Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients","volume":"127","author":"DeLacey","year":"2019","journal-title":"Bone"},{"issue":"1","key":"2026081219562847600_dgag140-B30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00198-020-05548-0","article-title":"Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review","volume":"32","author":"Seefried","year":"2021","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026081219562847600_dgag140-B31","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s13023-022-02452-0","article-title":"Health-related quality of life of X-linked hypophosphatemia in Spain","volume":"17","author":"Yanes","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"2026081219562847600_dgag140-B32","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s40618-025-02596-3","article-title":"Predictors of response to burosumab in adults with X-linked hypophosphatemia: real-world data from an Italian cohort","volume":"48","author":"Arcidiacono","year":"2025","journal-title":"J Endocrinol Invest"},{"key":"2026081219562847600_dgag140-B33","doi-asserted-by":"crossref","first-page":"20406223241247643","DOI":"10.1177\/20406223241247643","article-title":"Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis","volume":"15","author":"Boot","year":"2024","journal-title":"Ther Adv Chronic Dis"},{"issue":"10","key":"2026081219562847600_dgag140-B34","doi-asserted-by":"crossref","first-page":"e998","DOI":"10.1210\/clinem\/dgad223","article-title":"Effects of burosumab treatment on mineral metabolism in children and adolescents with X-linked hypophosphatemia","volume":"108","author":"Ewert","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026081219562847600_dgag140-B35","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00223-025-01433-2","article-title":"Real-world effectiveness of burosumab in adults with X-linked hypophosphataemia (XLH) in the UK","volume":"116","author":"Bubbear","year":"2025","journal-title":"Calcif Tissue Int"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag140\/67786801\/dgag140.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/9\/2466\/67786801\/dgag140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/9\/2466\/67786801\/dgag140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T23:56:35Z","timestamp":1786578995000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/9\/2466\/8586795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,4,4]]},"published-print":{"date-parts":[[2026,8,13]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag140","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,4,4]]}}}